German drugmaker Merck KGaA plans to ask a European watchdog to review a negative opinion issued on multiple sclerosis drug cladribine last month that said the drug's risks outweighed its benefits.
"Merck is committed to the potential of cladribine tablets to meet an unmet medical need as an oral, short-course, disease-modifying drug for multiple sclerosis," the group said in a statement on Monday.
The drug was dealt a major blow in September when the Committee for Medicinal Products for Human Use (CHMP), whose view is invariably adopted by the European Commission for approval of decisions, found that the drug may not be fit for approval. [ID:nLDE68N04J]... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1629
- Similar Topics
- Last post